Early and Sensitive Detection of Cisplatin-Induced Kidney Injury Using Novel Biomarkers
NBMs accurately and timely detected cisplatin exposure and identified "sub-clinical" DIKI undetected by standard acute kidney injury (AKI) criteria, highlighting the limitations of current functional BMs in estimating the true DIKI incidence.
Authors
- Michael Brad Strader (ORCID: https://orcid.org/0000-0002-5089-8539)
- Xavier Benain (ORCID: https://orcid.org/0000-0002-3414-1325)
- Nunzio Camerlingo (ORCID: https://orcid.org/0000-0003-3222-2479)
- Gary S. Friedman (ORCID: https://orcid.org/0000-0003-2479-328X)
- Shiran Shapira (ORCID: https://orcid.org/0000-0002-3974-5910)
- Stefan Sultana (ORCID: https://orcid.org/0000-0001-9767-1481)
- Patrick Murray (ORCID: https://orcid.org/0000-0001-8516-1839)
- Nadir Aber
Institutions
- University College Dublin (IE)
- Tel Aviv University (IL)
- Tel Aviv Sourasky Medical Center (IL)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1016/j.ekir.2025.01.035
- Citations
- 4
- Primary Topic
- Chemotherapy-induced organ toxicity mitigation
- Type
- article
- Field-Weighted Citation Impact
- 5.89
Funders
- European Federation of Pharmaceutical Industries and Associations
- Innovative Health Initiative
- European Commission